Skip to main content

Advertisement

Table 1 Baseline characteristics and follow-up information of the gout and control groups

From: Gout and the risk of dementia: a nationwide population-based cohort study

  No gout (n = 114,742) Gout (n = 287,69) P -value
Baseline characteristics    
 Age 63.5 ± 9.7 63.5 ± 9.7 0.979
 Male 72,642 (63.3%) 18,254 (63.4%) 0.724
 Hypertension 38,947 (33.9%) 15,613 (54.3%) <0.001
 Hyperlipidemia 11,177 (9.7%) 6,566 (22.8%) <0.001
 Diabetes mellitus 18,968 (16.5%) 6,504 (22.6%) <0.001
 Coronary artery disease 16,937 (14.8%) 6,146 (21.4%) <0.001
 Heart failure 3,604 (3.1%) 1,533 (5.3%) <0.001
 Arrhythmia 11,678 (10.2%) 3,800 (13.2%) <0.001
 Chronic obstructive pulmonary disease 21,789 (19.0%) 6,590 (22.9%) <0.001
 Asthma 7,892 (6.9%) 2,698 (9.4%) <0.001
 Stroke 5,771 (5.0%) 1,611 (5.6%) <0.001
 Malignancy 5,484 (4.8%) 1,337 (4.6%) 0.341
 Chronic kidney disease 5,128 (4.5%) 2,479 (8.6%) <0.001
 Parkinson's disease 1,296 (1.1%) 290 (1.0%) 0.077
Follow-up information    
All dementia types    
 Follow-up duration 4.3 ± 2.1 4.4 ± 2.0 <0.001
 New cases (incidence density) 5,905 (11.9) 1,214 (9.5)  
 Vascular dementia    
 Follow-up duration 4.4 ± 2.0 4.5 ± 2.0 <0.001
 New cases (incidence density) 991 (2.0) 210 (1.6)  
Non-vascular dementia    
 Follow-up duration 4.3 ± 2.0 4.5 ± 2.0 <0.001
 New cases (incidence density) 4,914 (9.9) 1,004 (7.8)  
Alzheimer's disease    
 Follow-up duration 4.4 ± 2.0 4.5 ± 2.0 <0.001
 New cases (incidence density) 542 (1.1) 102 (0.8)  
  1. Follow-up duration is expressed in person-years. Incidence density values are per 1000-person-years.